In the realm of biochemical research and protein engineering, the adalimumab peptide sequence represents a cornerstone of modern monoclonal antibody analysis. As someone deeply interested in the structural biology of therapeutic proteins, I have spent significant time examining the architecture of this recombinant human IgG1 monoclonal antibody. Understanding its primary structure is essential for anyone involved in analytical chemistry, peptide mapping, or the development of pharmacokinetic Figure 4:Sequence map for adalimumab heavy (HC) and light chains (LC) obtained by FASP tryptic digestion and chromatographic procedures described. The numbers Read more (PK) assays.
The Architectural Complexity of Adalimumab
Adalimumab is a monoclonal IgG1 antibody composed of two heavy (H) chains and two light (L) chains. This complex glycoprotein structure is what allows it to function as a high-affinity molecule targeting tumor necrosis factor-alpha (TNF-α). When analyzing the amino acid sequences of this molecule, researchers often look at the sequence map for adalimumab heavy (HC) and light chains (LC) to understand its variable and constant regions.
Each light chain typically consists of 214 amino acid residues, while each heavy chain is composed of 451 amino acid residues, bringing the total to 1,330 amino acids. The primary amino acid sequence of Adalimumab defines its binding specificity, which is why researchers often cross-reference these sequences with the IMGT/mAb-DB record.
Analytical Methods and Peptide Mapping
To achieve greater than 93% sequence coverage during mass spectrometry workflows, professionals uti Explore the latest medical news and research findings related to Adalimumab. This page aggregates current publications and studies from trusted medical sources lize tryptic digestion. The goal is to reach a high-resolution sequence map of Adalimumab heavy chain Fab fragment and the corresponding light chain components.
One specific se Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. X-ray structures of the apo and TNFα-bound Fab fragment of adalimumab Read more quence that frequently appears in literature is the APYTFGQGTK peptide. This peptide is derived from the light chain of the antibody and is highly valued in Adalimumab, sold under the brand name Humira and others,is a disease-modifying antirheumatic drug and monoclonal antibodyused to treat rheumatoid arthritis.Read more research for its universal locatio US20150158943A1 - Methods related to adalimumab n, making it a reliable marker for identification. In my experience with laboratory workflows, using synthetic peptides derived from Adalimumab is an excellent way to standardize assays, particularly when monitoring antibody concentrations or evaluating structural integrity.
Key Structural Components and Variation
When discussing adalimumab, it is crucial to note that it is a fully human antibody, meaning it has no non-human or artificially-fused human sequences. This structural purity is a resu Explore the latest medical news and research findings related to Adalimumab. This page aggregates current publications and studies from trusted medical sources lt of its manufacturing process in CHO cells.
For those studying the amino acid sequence in detail, the heavy chain begins with the characteristic region: `EVQLVESGGG LVQPGRSLRL SCAASGFTFD DYAMHWVRQA PGKGLEWVSA ITWNSGHIDY`. This sequence is fundamental to the molecule's interaction with its antigen.
Practical Considerations for Researchers
If you are exploring the latest medical news and research findings related to Adalimumab, you will find that the adalimumab light- and heavy-chain sequences are subject to rigorous quality control. Whether you are performing a peptide map or validating a formulation, the following points are essential for your documentation:
* Structural Integrity: The molecule is characterized by its composition of two H and two L polypeptide chains.
* Identification: The APYTFGQGTK peptide serves as a vital tool for verifying the presence and orientation of the light chain.
* Documen (A2)Sequence map of Adalimumab heavy chain Fab fragment. Relevant candidate immunogenic peptide epitopes are reported. (B1) Adalimumab light chain Fab fragment Read more tation: Always refer to the Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record for the most accurate, peer-reviewed data.
Conclusion
W Adalimumab hether you are performing amino acid sequence alignments or developing a new assay, the Adalimumab sequence remains a fascinating subject of study. By focusing on the precise amino acid sequences and utilizing established peptide mapping techniques, researchers can deepen their understanding of how this recombinant human IgG1 monoclonal antibody maintains its stability and functionality. This is a monoclonal anti-tumor necrosis factor alpha antibody that continues to be a gold standard in protein research.
*Disclaimer: This content is for informational and research purposes only. Adalimumab is a specialized therapeutic agent, and all research involving such molecules should be conducted in an appropriate laboratory setting by qualified professionals.*